Gland Pharma Secures USFDA Approval for Acetaminophen Injection for Pain Management
核心洞察
Gland Pharma has received USFDA (搜索) approval for Acetaminophen Injection (10 mg/mL) in 500mg/50mL and 1000mg/100mL bag formulations for pain management.
The injectable product is indicated for mild to moderate pain management in patients 2 years and older, and for moderate to severe pain when used with opioid analgesics.
With US sales of approximately $55 million for the twelve months ending February 2025, Gland Pharma plans to launch the product through a marketing partner soon.
Hyderabad-based Gland Pharma Limited has secured approval from the United States Food and Drug Administration (USFDA (搜索)) for its Acetaminophen Injection, 10 mg/mL, available in 500mg/50mL and 1000mg/100mL bag formulations.
The injectable formulation has been confirmed as bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Acetaminophen Injection manufactured by B. Braun Medical (搜索), Inc. This approval strengthens Gland Pharma's position in the injectable pharmaceuticals market in the United States.
Therapeutic Applications and Market Potential
The newly approved Acetaminophen Injection is indicated for multiple pain management scenarios, including:
- Management of mild to moderate pain in adult and pediatric patients 2 years and older
- Treatment of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older
According to IQVIA data, the product recorded approximately US $55 million in sales for the twelve-month period ending February 2025 in the United States market, indicating significant commercial potential for Gland Pharma's generic version.
Commercialization Strategy
Gland Pharma has announced plans to launch the Acetaminophen Injection through its marketing partner in the near future. This approach aligns with the company's established strategy of leveraging partnerships for market access in the competitive US pharmaceutical landscape.
The approval comes as part of Gland Pharma's ongoing efforts to expand its injectable product portfolio in the US market. The company, which specializes in generic injectable formulations, has been steadily building its presence in the US pharmaceutical sector through strategic approvals and launches.
Company Background
Gland Pharma Limited is a generic injectable-focused pharmaceutical company based in Hyderabad, India. The company has established itself as a significant player in the development and manufacturing of injectable formulations, with a growing presence in international markets, particularly the United States.
This approval follows other recent regulatory successes for the company, including USFDA (搜索) approval for Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, which was also deemed bioequivalent and therapeutically equivalent to Hospira, Inc.'s Vitamin K1 Injectable Emulsion USP (10 mg/mL).